We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
Read MoreHide Full Article
Key Takeaways
Hims & Hers is scaling its personalized, subscription-based care model into new markets and therapies.
HIMS is entering Canada and expanding in Europe via ZAVA to support weight loss and localized care.
An $870 million convertible notes offering will fund HIMS' AI-driven diagnostics and infrastructure expansion.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has built a business model centered on personalized, subscription-based care that prioritizes convenience, accessibility and affordability. It offers recurring treatment plans for a wide range of conditions — from dermatology and mental health to sexual wellness and weight management — through its digital platform. Customers can customize delivery cadences and treatment options, while the integrated fulfillment and telehealth systems ensure seamless care continuity. This model not only supports individualized care but also provides Hims & Hers with predictable recurring revenue and strong margins through technology-driven efficiency and scale.
The company continues to expand this scalable model globally and across new therapeutic areas. Its recent planned entry into Canada aligns with the anticipated availability of generic semaglutide, enabling Hims & Hers to offer lower-cost, clinically supported weight loss programs at scale. The acquisition of ZAVA, an European telehealth provider, further extends its reach across the U.K., Germany, France and Ireland, enhancing its subscription-based ecosystem and localized care delivery.
To support this growth, Hims & Hers completed an $870 million convertible notes offering, aimed at accelerating expansion and advancing AI-driven personalization and diagnostics. Combined with its vertically integrated infrastructure — including in-house pharmacies and compounding facilities — these investments reinforce a scalable, technology-enabled care network capable of delivering individualized, recurring treatments efficiently and profitably across markets.
TEM & LFMD’s Personalized Digital Health Platforms
Tempus AI, Inc. (TEM - Free Report) employs a highly scalable, AI-driven precision medicine model built around personalized diagnostics, multimodal data integration and strategic partnerships. Tempus’ AI platform leverages one of the world’s largest libraries of genomic and clinical data to deliver tailored insights for physicians and life sciences clients. Its acquisition of Paige enhanced its digital pathology capabilities, while collaborations with ARPA-H and Whitehawk Therapeutics advanced biomarker-guided oncology research. The FDA’s special clearance for its Tempus Pixel device further demonstrates its commitment to expanding AI-powered diagnostic solutions.
LifeMD, Inc. (LFMD - Free Report) operates a vertically integrated, subscription-based telehealth and pharmacy platform designed to scale through digital care delivery. LifeMD’s model combines virtual primary care, behavioral health and chronic condition management with its proprietary LifeMD+ membership program, offering continuous personalized care through recurring virtual consultations and medication fulfillment. LifeMD’s recent initiatives include the launch of Ozempic and Wegovy programs through partnerships with Novo Nordisk and Lilly, expanding access to branded GLP-1 therapies, and the divestiture of WorkSimpli Software to concentrate fully on virtual healthcare.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 71.7% year to date, outperforming the industry’s growth of 20%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.4X is lower than the industry’s average of 5.6X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests an 81.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has built a business model centered on personalized, subscription-based care that prioritizes convenience, accessibility and affordability. It offers recurring treatment plans for a wide range of conditions — from dermatology and mental health to sexual wellness and weight management — through its digital platform. Customers can customize delivery cadences and treatment options, while the integrated fulfillment and telehealth systems ensure seamless care continuity. This model not only supports individualized care but also provides Hims & Hers with predictable recurring revenue and strong margins through technology-driven efficiency and scale.
The company continues to expand this scalable model globally and across new therapeutic areas. Its recent planned entry into Canada aligns with the anticipated availability of generic semaglutide, enabling Hims & Hers to offer lower-cost, clinically supported weight loss programs at scale. The acquisition of ZAVA, an European telehealth provider, further extends its reach across the U.K., Germany, France and Ireland, enhancing its subscription-based ecosystem and localized care delivery.
To support this growth, Hims & Hers completed an $870 million convertible notes offering, aimed at accelerating expansion and advancing AI-driven personalization and diagnostics. Combined with its vertically integrated infrastructure — including in-house pharmacies and compounding facilities — these investments reinforce a scalable, technology-enabled care network capable of delivering individualized, recurring treatments efficiently and profitably across markets.
TEM & LFMD’s Personalized Digital Health Platforms
Tempus AI, Inc. (TEM - Free Report) employs a highly scalable, AI-driven precision medicine model built around personalized diagnostics, multimodal data integration and strategic partnerships. Tempus’ AI platform leverages one of the world’s largest libraries of genomic and clinical data to deliver tailored insights for physicians and life sciences clients. Its acquisition of Paige enhanced its digital pathology capabilities, while collaborations with ARPA-H and Whitehawk Therapeutics advanced biomarker-guided oncology research. The FDA’s special clearance for its Tempus Pixel device further demonstrates its commitment to expanding AI-powered diagnostic solutions.
LifeMD, Inc. (LFMD - Free Report) operates a vertically integrated, subscription-based telehealth and pharmacy platform designed to scale through digital care delivery. LifeMD’s model combines virtual primary care, behavioral health and chronic condition management with its proprietary LifeMD+ membership program, offering continuous personalized care through recurring virtual consultations and medication fulfillment. LifeMD’s recent initiatives include the launch of Ozempic and Wegovy programs through partnerships with Novo Nordisk and Lilly, expanding access to branded GLP-1 therapies, and the divestiture of WorkSimpli Software to concentrate fully on virtual healthcare.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 71.7% year to date, outperforming the industry’s growth of 20%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.4X is lower than the industry’s average of 5.6X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests an 81.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.